Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Pulmonary Arterial Hypertension
NCT03057028Phase 1Completed
- Sponsor
- Virginia Commonwealth University
- Start
- Apr 2016
- Primary completion
- Jun 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anakinra in pulmonary arterial hypertension (PAH), sponsored by Virginia Commonwealth University. Primary endpoints: Peak Oxygen Consumption at 14 days and Ventilatory Efficiency at 14 days. Started Apr 2016; status: completed.
02
Drugs
anakinra
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03057028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03057028.